急性肺栓塞患者大出血:COPE 研究结果
COPE 是一项前瞻性多中心研究,纳入 5213 例急性肺栓塞患者,按 ISTH 标准评估 30 天内大出血(MB)。159 例(3.1%)发生 MB,早期 78 例、晚期 81 例;溶栓者 MB 发生率为 12.9%,未溶栓者为 2.5%。早期与晚期 MB 的独立预测因素不同,四种出血表型预测 MB 的效能与 PE-SARD、BACS 和 VTE-Bleed 评分相似。
要点
- 急性肺栓塞 30 天内大出血发生率 3.1%,溶栓者 12.9% 远高于未溶栓者 2.5%。
- 早期与晚期大出血的独立预测因素不同,溶栓仅与早期及 30 天 MB 相关。
- 四种出血表型预测 30 天 MB 的效能与 PE-SARD、BACS、VTE-Bleed 评分相似。
核心结论
- 急性肺栓塞患者 30 天内早期与晚期大出血的危险因素不同。
- 基于出血表型的分层策略在识别大出血风险方面与单纯出血预测因素分层策略效能相似。
研究设计与样本
- 前瞻性多中心研究,纳入 5213 例急性肺栓塞患者。
- 主要结局为 30 天随访期间按 ISTH 标准定义的大出血,并按诊断后 <7 天和 ≥7 天分为早期与晚期。
主要发现
- 5213 例中 159 例(3.1%)发生大出血,其中早期 78 例、晚期 81 例。
- 溶栓治疗者大出血发生率为 12.9%,未溶栓者为 2.5%。
- 活动性肿瘤、既往出血、痴呆、贫血、晕厥和溶栓是早期大出血及 30 天大出血的独立预测因素。
- 活动性肿瘤、既往出血和贫血是晚期大出血的独立预测因素。
- 识别出四种出血表型:#1 既往 VTE/雌激素使用者、#2 无诱因 PE、#3 肿瘤患者、#4 合并症多的脆弱患者;表型 #1 大出血风险低于其他表型,风险从 #1 到 #4 呈升高趋势。
关键数值与推荐
- 大出血按 ISTH 标准定义,发生于 30 天随访期间。
- 早期大出血为 PE 诊断后 <7 天,晚期为 ≥7 天。
- 出血表型预测 30 天大出血的效能与 PE-SARD、BACS 和 VTE-Bleed 相似。
临床怎么用
- 对急性肺栓塞患者应区分早期与晚期大出血风险,关注活动性肿瘤、既往出血、贫血等预测因素。
- 溶栓治疗者大出血风险明显升高,需权衡获益与出血风险。
- 出血表型分层可作为识别大出血高风险患者的策略之一,效能与现有出血风险评分相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with acute pulmonary embolism (PE), major bleeding (MB) is the counterbalance for anticoagulant and thrombolytic treatment. We aimed to assess independent predictors of MB, evaluate the performance of available bleeding risk scores, and identify bleeding-phenotypes in patients with acute PE from a prospective, multicentre study. METHODS: The primary outcome was MB defined according to ISTH criteria occurring during 30-day follow-up. MBs were classified as early (<7 days) and late (≥7 days) based on days from PE diagnosis. RESULTS: Among 5213 patients with acute PE, 159 had MB (3.1%), 78 as early, and 81 as late events. MB occurred in 12.9% and 2.5% of patients treated versus not treated with thrombolysis. Active cancer, previous bleeding, dementia, anemia, syncope, and thrombolysis were independent predictors of early MB and of MB at 30 days; active cancer, previous bleeding and anemia were independent predictors of late MB.Four bleeding-phenotypes were identified; phenotype#1=previous VTE/estrogen users, #2=unprovoked PE, #3=cancer patients, #4=fragile patients with comorbidities. The risk of MB was lower in the previous VTE (#1) bleeding-phenotype in comparison to the others, with a trend toward increased risk from phenotype #1 to #4. Performance of phenotypes to predict MB at 30-days was similar to that of PE-SARD, BACS and VTE-Bleed. CONCLUSIONS: In patients with acute PE, risk factors for early and late MB within 30 days differ. Compared to stratification strategies that solely based on bleeding predictors, phenotyping appears to offer similar accuracy in identifying patients at risk for MB.
引用
- Becattini C, Cimini LA, Vatrano M, et al. Major bleeding in patients with acute pulmonary embolism: results from the COPE study. Eur Respir J. 2026. PMID: 42988386. doi:10.1183/13993003.00119-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。